Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2016

View Archived Issues

Kalvista Pharmaceuticals describes KLKB1 inhibitors

SatRx discloses first market registration of antidiabetic drug gosogliptin in Russia

Aptose Biosciences and Crystalgenomics enter global license deal for the development of CG-026806

Insmed withdraws Arikayce MAA, with plans to resubmit

Darvulumab monotherapy shows early evidence of clinical benefit in NSCLC patients

Momenta Pharmaceuticals doses first volunteers in phase I trial for M-281

Kempharm files amendment request with FDA regarding Apadaz's NDA

Addex Therapeutics reports positive results on ADX-71441

Shionogi patents P2X3 and/or P2X2/3 receptor antagonists

Sichuan Haisco Pharmaceutical discloses anticancer agents

reMYND develops agents for amyloid-related diseases

Arrowhead Pharmaceuticals begins phase I/II trial of ARC-521

Investigators from SIMM and GIBH present EGFR inhibitors

RN-983 shows promising activity in the ovalbumin allergic mouse model of asthma

GM-604 receives E.U. orphan drug designation for ALS

Results presented for emibetuzumab with or without erlotinib in patients with NSCLC

Mologen shifts from research to product- and market-oriented company

Joslin Diabetes Center announces collaboration with Sanofi for diabetes treatment exploration

Alnylam Pharmaceuticals begins phase I trial of ALN-TTRsc02

Merck & Co. signs definitive agreement to acquire Afferent Pharmaceuticals

Phase I data on TD-1473 support progression into ulcerative colitis trial

Vemurafenib may enhance RAI efficacy in BRAF-mutant thyroid cancer patients

PPMD awards grant to University of Washington to develop gene therapy for Duchenne

Lilly grants USD 1 million to sponsor development of the ARMR

Remissions seen with CD19-specific CAR T cells retreatment in pediatric patients with ALL

Debiopharm International starts phase II trial for Debio-1143

Venetoclax combined with bortezomib and dexamethasone show acceptable safety profile in MM

Sophiris Bio discloses results for phase IIa trial of topsalysin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.